|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 226-232.
Prepublished online as a Blood First Edition Paper on August 17, 2004; DOI 10.1182/blood-2004-05-1768.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl)
Shan Zeng,
Zhiheng Xu,
Stan Lipkowitz, and
Jack B. Longley
From the Departments of Dermatology and Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; and Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD.
Activation of the KIT receptor tyrosine kinase contributes to the pathogenesis of several human diseases, but the mechanisms regulating KIT signaling have not been fully characterized. Here, we show that stem cell factor (SCF), the ligand for KIT, induces the interaction between KIT and Cbl proteins and their mutual degradation. Upon SCF stimulation, KIT binds to and induces the phosphorylation of Cbl proteins, which in turn act as E3 ligases, mediating the ubiquitination and degradation of KIT and themselves. Tyrosine kinase binding and RING finger domains of Cbl are essential for Cbl-mediated ubiquitination and degradation of KIT. We propose a negative feedback loop controlling the SCF-KIT signaling pathway, in which SCF activates KIT. The activated KIT in turn induces phosphorylation and activation of Cbl proteins. The Cbl proteins then bind and direct the degradation of activated KIT, leading to down-regulation of KIT signaling. (Blood. 2005;105:226-232)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Abbas, G. Rotmans, B. Lowenberg, and P. J.M. Valk
Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias
Haematologica,
October 1, 2008;
93(10):
1595 - 1597.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Bachelet, A. Munitz, B. Berent-Maoz, D. Mankuta, and F. Levi-Schaffer
Suppression of Normal and Malignant Kit Signaling by a Bispecific Antibody Linking Kit with CD300a
J. Immunol.,
May 1, 2008;
180(9):
6064 - 6069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rathinam, C. B.F. Thien, W. Y. Langdon, H. Gu, and R. A. Flavell
The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells
Genes & Dev.,
April 15, 2008;
22(8):
992 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tu, L. Fan, K. Tao, W. Zhu, J. Li, and G. Lu
Stem cell factor affects fate determination of human gonocytes in vitro
Reproduction,
December 1, 2007;
134(6):
757 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Reddi, G. Ying, L. Duan, G. Chen, M. Dimri, P. Douillard, B. J. Druker, M. Naramura, V. Band, and H. Band
Binding of Cbl to a Phospholipase C{gamma}1-docking Site on Platelet-derived Growth Factor Receptor beta Provides a Dual Mechanism of Negative Regulation
J. Biol. Chem.,
October 5, 2007;
282(40):
29336 - 29347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sargin, C. Choudhary, N. Crosetto, M. H. H. Schmidt, R. Grundler, M. Rensinghoff, C. Thiessen, L. Tickenbrock, J. Schwable, C. Brandts, et al.
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Blood,
August 1, 2007;
110(3):
1004 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Caligiuri, R. Briesewitz, J. Yu, L. Wang, M. Wei, K. J. Arnoczky, T. B. Marburger, J. Wen, D. Perrotti, C. D. Bloomfield, et al.
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia
Blood,
August 1, 2007;
110(3):
1022 - 1024.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
